Sweden’s most promising startups
Sting has contributed to the development of over 100 companies, primarily in ICT, Internet/media, cleantech, sustainability, health and life science. We offer two programmes: Sting Accelerate and Sting Incubate. Here you can read about the companies who are currently a part of Sting and also get to know some more about our alumni companies.
About 90 percent of prostate cancers are non-aggressive whereas the rest are aggressive tumours, which have to be treated with radical methods. Present diagnostics can’t separate these forms which bring about severe decisions. This dilemma is the basis for the novel test PCPT (Prostate Cancer Prediction Test).